NASDAQ:MDGL

Madrigal Pharmaceuticals Stock News

etoro logo Buy MDGL
*Your capital is at risk
$513.43
+0.550 (+0.107%)
At Close: Jun 23, 2026
Amarin reports better than expected financial numbers for second quarter. CytoDyn reports positive DSMC opinion for COVID-19 trial.
CONSHOHOCKEN, Pa., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its second quarter 2020 financial results and highlights: “The Madrigal team and ou
Fractyl's first close of $55 million will be used to support the Revita T2Di pivotal US clinical trial of Revita DMR to treat type 2 diabetes.
Merck & Co is to pay $10 million to Hanmi to repurpose a drug discarded by Johnson & Johnson in obesity into a therapy for the fatty liver disease also known as NASH.
(AOF) - Genfit annonce que les données décrivant la dérivation et la validation de NIS4 ont été acceptées pour publication dans The Lancet Gastroenterology & Hepatology. NIS4 est la technologie
(AOF) - Genfit annonce que les données décrivant la dérivation et la validation de NIS4 ont été acceptées pour publication dans The Lancet Gastroenterology & Hepatology. NIS4 est la technolo
ENTA earnings call for the period ending June 30, 2020.
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) ABIOMED, Inc. (NASDAQ: ABMD) (FDA approved the emergency use of Abiomed's Impella heart pump in combination...

Merck, Hanmi sign $870M deal for NASH drug

05:43pm, Tuesday, 04'th Aug 2020
Hanmi will retain options for the drug, efinopegdutide, in Korea under the deal, in which Merck is paying the Seoul-based company $10 million upfront and up to $860 for development, regulatory and com
Cambridge Investment Research Advisors Inc. boosted its holdings in Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) by 4.7% during the 2nd quarter, according to the company in its most recent filing with t
DRRX earnings call for the period ending June 30, 2020.
Merck and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efinopegdutide, an Investigational Once-Weekly Therapy for NASH
The company is hoping to close its seed funding round in the next six months and aims to be in a position to seek regulatory approval for its lead asset, PLX888, in acute alcoholic hepatitis in 2023.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE